Companies attending
Companies attending
Emerging companies across the resources, life sciences and technology sectors will be attending and hosting meetings at the Ignite Investment Summit Hong Kong on 15 – 16 October 2025.
If you’re a qualified investor who would like to arrange 1-on-1 meetings with any of these companies, click here for investor registration and access to our Meeting Planner which contains profiles of each participating company, their projects, and management teams.
Emerging companies across the resources, life sciences and technology sectors will be attending and hosting meetings at the Ignite Investment Summit Hong Kong on 15 – 16 October 2025.
If you’re a qualified investor who would like to arrange 1-on-1 meetings with any of these companies, click here for investor registration and access to our Meeting Planner which contains profiles of each participating company, their projects, and management teams.
Resources companies
| Company Name | Exchange | Ticker | Stage | Commodity | Project Location | Market Cap |
|---|---|---|---|---|---|---|
| ACG Metals | LON | ACG | Production | Copper | Turkey | $140.85M 🇬🇧 |
| Aeris Resources | ASX | AIS | Production | Copper, Gold | Australia | $217.87M 🇦🇺 |
| Altair Minerals | ASX | ALR | Explorer | Gold | South America | $70.93M 🇦🇺 |
| Aston Bay | CVE | BAY | Exploration | Gold, Base Metals | USA, Canada | $15.18M 🇨🇦 |
| Bahia Metals Corp | Private | Private | Exploration | Nickel | Brazil | Private |
| Battery Age Minerals | ASX | BM8 | Exploration | Zinc, Lead, Germanium, Silver, Gold, Lithium | Austria, Argentina, Canada | $12.59M 🇦🇺 |
| Blackstone Minerals | ASX | BSX | Exploration | Nickel, Gold, Cobalt | Vietnam & Canada | $113.26M 🇦🇺 |
| Challenger Gold | ASX | CEL | Exploration | Gold, Copper | Argentina, Ecuador, South Africa | $248.01M 🇦🇺 |
| Critica Limited | ASX | CRI | Exploration | Rare Earths | Australia | $56.66M 🇦🇺 |
| DY6 Metals | ASX | DY6 | Exploration, Development | Rare Earths, Critical Metals | Malawi | $26.96M 🇦🇺 |
| Empire Metals | LON | EEE | Exploration, Development | Titanium | Western Australia | $302.20M 🇬🇧 |
| Estrella Resources | ASX | ESR | Exploration, Development | Manganese | Timor-Leste | $87.16M 🇦🇺 |
| GBM Resources | ASX | GBZ | Exploration, Development | Gold, Copper | Australia | $112.14M 🇦🇺 |
| Gorilla Gold Mines | ASX | GG8 | Exploration | Gold | Australia | $271.38M 🇦🇺 |
| iMetal Resources | TSXV, OTCQB, FRA | IMR, IMRFF, A7VA | Exploration | Gold, Silver, Copper, Graphite | Canada | $5.60M 🇨🇦 |
| Kalgoorlie Gold Mining | ASX | KAL | Exploration | Gold | Western Australia | $14.13M 🇦🇺 |
| Li-FT Power | TSXV, OTCQX, FRA | LIFT, LIFFF, WS0 | Exploration, Development | Lithium | Canada | $121.65M 🇦🇺 |
| MDF Global | Private | Private | Exploration | Critical Metals | - | Private |
| OD6 Metals | ASX | OD6 | Exploration, Development | Rare Earths, Copper | Australia | $9.46M 🇦🇺 |
| Odyssey Gold | ASX | ODY | Exploration | Gold | Western Australia | $27.31M 🇦🇺 |
| Pacgold | ASX | PGO | Exploration | Gold | Australia | $15.83M 🇦🇺 |
| Pinnacle Silver & Gold Corp | TSXV, OTC, PSGCF, FRA | PINN, PSGCF, P9J | Exploration, Development | Gold, Silver | Canada, Mexico | $8.95M 🇨🇦 |
| Pure One | ASX | PH2 | Production | Hydrogen | Australia | $34.45M 🇦🇺 |
| Questcorp | CSE | QQQ | Exploration | Copper | North America | $9.74M 🇨🇦 |
| Rare X | ASX | REE | Development | Rare Earth, Critical Minerals | Western Australia | $19.95M 🇦🇺 |
| Silver 47 | TSX, OTCQB, FRA | AGA, AAGAF, QP2 | Exploration | Silver, Copper, Gold | North America | $100.57M 🇨🇦 |
| St George Mining | ASX | SGQ | Exploration, Development | Critical Metals | Western Australia | $134.76M 🇦🇺 |
| Toubani Resources | ASX | TRE | Exploration, Development | Gold | West Africa | $122.85M 🇦🇺 |
| Trigg Minerals | ASX | TMG | Exploration | Antimony, Tungsten | USA, Australia | $240.7M 🇦🇺 |
| West Coast Silver | ASX | WCE | Exploration, Development | Silver | Western Australia | $70.76M 🇦🇺 |
| Western Copper & Gold | TSX | WRN | Development | Copper, Gold | Canada | $399.33M 🇨🇦 |
| White Cliff Minerals | ASX | WCN | Exploration | Copper, Gold, Silver, Uranium | Canada | $54.86M 🇦🇺 |
Technology companies
| Company Name | Exchange | Ticker | Sub-Sector | Services / Products | Market Cap |
|---|---|---|---|---|---|
| dorsaVi | ASX | DVL | Biotechnology | A biotechnology company focused on developing innovative motion analysis device technologies. | $53.71M 🇦🇺 |
| Integrated Research | ASX | IRI | IT / Software | Provides user experience and performance management solutions for payment transactions and collaborative systems. | $77.15M 🇦🇺 |
| Nano One | TSX, FF, OTCQB | NANO, LBMB, NNOMF | Battery technology | Nano One® transforms lithium-ion battery cathode production with scalable, cost-effective, and innovative One-Pot technology. | $127.15M 🇨🇦 |
| Nanoveu | ASX | NVU | Nanotechnology | Deploys nanotechnology for protective films and coatings, including their Nanoshield product range and EyeFly3D. | $89.18M 🇦🇺 |
| TZ | ASX | TZL | IT / Software | Offers smart lockers for IT asset management, package asset management, and secure employee storage solutions. | $13.19M 🇦🇺 |
| Vection Technologies | ASX | VR1 | IT / Software | Focuses on real-time technologies for industrial companies’ digital transformation, with a strong focus on Industry with its unique Virtual Reality, Software and dedicated SaaS model approach. | $101.47M 🇦🇺 |
Life sciences companies
| Company Name | Exchange | Ticker | Stage | Services / Products | Market Cap |
|---|---|---|---|---|---|
| Dimerix | ASX | DXB | Clinical stage | Develops drug candidates for inflammatory diseases, including kidney and respiratory conditions. | $313.30M 🇦🇺 |
| Neurizon | ASX | NUZ | Clinical stage | Develops innovative treatments for neurodegenerative diseases, centered on NUZ-001 (S-Monepantel). | $76.31M 🇦🇺 |
| Paradigm Biopharma | ASX | PAR | Late-stage drug development | Develops injectable pentosan polysulfate sodium (iPPS) for osteoarthritis treatment. | $119.03M 🇦🇺 |
| Race Oncology | ASX | RAC | Clinical stage | A clinical-stage biopharmaceutical company advancing RC220, a reformulated anti-cancer drug with a rich history and safety profile. It’s being developed for multiple oncology indications, focusing on cardioprotection and enhanced anti-cancer activity in solid tumors. | $791.12M 🇦🇺 |
| Syntara | ASX | SNT | Clinical stage | Targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. | $38.82M 🇦🇺 |